- Home
- PCF vs FBIO Comparison
PCF vs FBIO Comparison
Compare PCF & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCF | FBIO |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 91.0M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCF | FBIO |
|---|---|---|
| Price | $5.60 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 50.5K | ★ 460.7K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.36 | $1.75 |
| 52 Week High | $6.51 | $4.53 |
Technical Indicators
Market Signals| Indicator | PCF | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 63.03 |
| Support Level | $5.52 | $2.48 |
| Resistance Level | $5.69 | $3.89 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 73.46 | 88.40 |
Price Performance
Historical ComparisonAbout PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.